Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new antibody-drug conjugate (ADC) called mocertatug rezetecan (Mo-Rez) is showing impressive early results in platinum-resistant ovarian cancer, with a 62% response rate in a phase 1 trial. Responses lasted a median of over a year, and very few patients had to stop treatment due to side effects. A phase 3 trial is now underway to confirm these findings against standard of care.
Platinum-resistant ovarian cancer (PROC) is one of the toughest cancers to treat — current antibody-drug conjugates (ADCs) in this space offer modest response rates and can come with significant toxicity. Now, updated data from the phase 1 BEHOLD-1 trial suggest that a new B7-H4–targeted ADC, mocertatug rezetecan (Mo-Rez), could meaningfully raise the bar.
Presented at the 2026 ESMO Congress, the data show Mo-Rez delivering a 62% confirmed objective response rate at the phase 3 dose, with durable responses and a low discontinuation rate due to side effects — a combination that could challenge the role of currently approved ADCs in this setting.
By the Numbers:
Why it matters: Mo-Rez is now being tested head-to-head against standard of care in the phase 3 BEHOLD-Ovarian01 trial. If those results hold up, this drug could reshape treatment for PROC — a setting with significant unmet need and limited effective options.
